Andrea Tan
Stock Analyst at Goldman Sachs
(2.00)
# 3,099
Out of 5,120 analysts
53
Total ratings
42.5%
Success rate
-6.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $281.54 | +16.15% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $72.01 | +18.04% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $154.02 | +46.08% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $2.60 | +207.69% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $66.24 | -23.01% | 4 | May 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $39 → $27 | $11.60 | +132.76% | 6 | Mar 25, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $6.04 | -0.66% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $3.85 | -48.05% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $23.97 | -91.66% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.54 | +577.97% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $4 | $1.25 | +221.29% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $486.89 | -22.98% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $13.16 | +507.83% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $281.54
Upside: +16.15%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $72.01
Upside: +18.04%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $154.02
Upside: +46.08%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $2.60
Upside: +207.69%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $66.24
Upside: -23.01%
Day One Biopharmaceuticals
Mar 25, 2025
Maintains: Buy
Price Target: $39 → $27
Current: $11.60
Upside: +132.76%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $6.04
Upside: -0.66%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $3.85
Upside: -48.05%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $23.97
Upside: -91.66%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.54
Upside: +577.97%
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.25
Upside: +221.29%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $486.89
Upside: -22.98%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $13.16
Upside: +507.83%